This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smirnov, A.
Right arrow Articles by Nau, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smirnov, A.
Right arrow Articles by Nau, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2000, p. 767-770, Vol. 44, No. 3
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Gemifloxacin Is Effective in Experimental Pneumococcal Meningitis

A. Smirnov, A. Wellmer, J. Gerber, K. Maier, S. Henne, and R. Nau*

Department of Neurology, University of Göttingen, Göttingen, Germany

Received 7 June 1999/Returned for modification 19 September 1999/Accepted 29 November 1999

In a rabbit model of Streptococcus pneumoniae meningitis, 5 mg of gemifloxacin mesylate (SB-265805) per kg/h reduced the bacterial titers in cerebrospinal fluid (CSF) almost as rapidly as 10 mg of ceftriaxone per kg/h (Delta log CFU/ml/h ± standard deviation [SD], -0.25 ± 0.09 versus -0.38 ± 0.11; serum and CSF concentrations of gemifloxacin were 2.1 ± 1.4 mg/liter and 0.59 ± 0.38 mg/liter, respectively, at 24 h). Coadministration of 1 mg of dexamethasone per kg did not affect gemifloxacin serum and CSF levels (2.7 ± 1.4 mg/liter and 0.75 ± 0.34 mg/liter, respectively, at 24 h) or activity (Delta log CFU/ml/h ± SD, -0.26 ± 0.11).

* Corresponding author. Mailing address: University of Göttingen, Department of Neurology, Robert-Koch-Str. 40, D-37075 Göttingen, Germany. Phone: 49-551-398455. Fax: 49-551-398405. E-mail: rnau{at}gwdg.de.

Antimicrobial Agents and Chemotherapy, March 2000, p. 767-770, Vol. 44, No. 3
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Barrett, M. J, Login, I. S (2009). Gemifloxacin-Associated Neurotoxicity Presenting as Encephalopathy. The Annals of Pharmacotherapy 43: 782-784 [Abstract] [Full Text]  
  • MacGowan, A. P., Rogers, C. A., Holt, H. A., Wootton, M., Bowker, K. E. (2001). Pharmacodynamics of Gemifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model of Infection. Antimicrob. Agents Chemother. 45: 2916-2921 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»